kras mutation and glutathion glynac mutation: from undruggable to druggable in cancer What should we know about
What should we know about the 'undruggable' target KRAS? MedChemExpress Metabolic reprogramming in KRAS mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies ScienceDirect Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges PMC KRAS OriGene Technologies Inc.
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



